Doelmatig gebruik van antiretrovirale therapie
- Universiteit Radboud UMC Nijmegen
- Promovendus Msc Piter Oosterhof
- Promoters Prof.dr. David Burger Kees Brinkman
- Co-Promoters ds Matthijs van Luin
- Jaar 2019 - 2023
The landscape of drug development as well as clinical practice has been changing over the last decennium, with the increasing availability and use of biobased therapies. This research is now focusing on the use and therapeutic drug monitoring of biobased factor VIII therapies in hemophilia A patients.
Part 1: Optimizing ribavirin therapy in transplant recipients with a chronic hepatitis E virus infection by devoloping a NONMEM model for ribavirin. Part 2: Improving immunosuppressive therapy in liver transplant recipients by performing 2 RCT's in which different immunosuppresive strategies will be compared to modify the tacrolimus related toxicity in this population. Part 3: Evaluate the contribution of an outpatient medication service for liver transplant recipients.
Dit project onderzoekt de haalbaarheid van heruitgifte van orale oncolytica, door het bepalen van kostenbesparingen en het in kaart brengen van de visie van patiënten en stakeholders.